Relmada Therapeutics, Inc. RLMD Prepaid Research And Development
Prepaid Research And Development at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept rlmd:PrepaidResearchAndDevelopment.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s prepaid research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s prepaid research and development?
- Relmada Therapeutics, Inc. (RLMD) reported prepaid research and development of $866.6K in Q1 2026.
- How has Relmada Therapeutics, Inc.'s prepaid research and development changed year-over-year?
- Relmada Therapeutics, Inc.'s prepaid research and development increased by 225.9% year-over-year, from $265.9K to $866.6K.
- What is the long-term trend for Relmada Therapeutics, Inc.'s prepaid research and development?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s prepaid research and development has grown at a 11.2% compound annual growth rate (CAGR), from $291.8K to $496.5K.
- What does prepaid research and development mean?
- Cash payments made to third-party vendors, contract research organizations (CROs), or clinical sites in advance of research and development services being performed. This metric indicates the company's near-term pipeline activity and the scale of upcoming clinical trial commitments. High balances suggest significant ongoing or planned R&D efforts.